Kornimate/medical-research-clean huggingface dataset:
diaphragmatic atrophy related to mechanical ventilation

Conditions: Septic Shock; Acute Respiratory Distress

Summary: ventilatory support during critical phase result in inactivity of respiratory muscles especially diaphragm muscle. these inactivity also result in change of contractile capability and quick muscular atrophy. the aim of the study is to visualize the evolution of diaphragm thickness by echography during mechanical ventilation for patients with septic shock or acute respiratory distress syndrome and to compare with the evolution for patients under non-invasive ventilation and those with spontaneous ventilation. measurements will be performed at day 1, day 5 and day 10 (if patient still under a mode of ventilation or in the unit). the evolution of diaphragm thickness will also be compared to pectoralis muscle atrophy, which is not involved in ventilation, in order to assess respective effect of ventilatory inactivity and undernutrition linked to intensive care.


Eligibility criteria:
inclusion criteria: * age ≥18 years old * group 1 : under mechanical ventilation (time of mechanical ventilation for at least 5 days) * group 2 : under non-invasive ventilation * group 3 : spontaneous ventilation * non opposition of patient (groups 2 and 3) or non-opposition of patient family member (group 1) exclusion criteria: * known diaphragmatic paralysis * neurologic pathology with motor deficit * pregnancy or breast-feeding woman

Keywords: mechanical ventilation
morphine mouthwash for management of oral mucositis in patients with head and neck cancer

Conditions: Stomatitis

Summary: oral mucositis is a debilitating side effects of cancer treatment for which there is not much successful treatments at yet. the investigators are going to evaluate the effectiveness of topical morphine compared with a routine mouthwash in managing cancer treatment-induced mucositis. the investigators hypothesize that topical morphine is more effective and more satisfied by patients than the magic mouthwash in reducing severity of cancer treatment-induced oral mucositis.


Eligibility criteria:
inclusion criteria: * head and neck cancer patients * severe oral mucositis; grade iii or iv of the world health organization (who) rating of global mucositis * willingness to participate exclusion criteria: * history of severe renal or hepatic insufficiency * collagen-vascular disease * allergic reaction to morphine * current smokers or alcohol users * pregnant women

Keywords: mucositis topical morphine pain head and neck carcinoma
clinical isolation syndrome of spinal cord and multiple sclerosis

Conditions: Clinical Isolation Syndrome of Spinal Cord; Multiple Sclerosis

Summary: the purpose of this study was to investigate the factors that influence the progression of patients with clinically isolated spinal cord syndrome to multiple sclerosis.

this study included patients who were first diagnosed with clinically isolated spinal cord syndrome admitted to the department of neurology, peking university third hospital between january 2010 and november 2020. according to the result of the outcome is divided into multiple sclerosis and outcome group, analyzing the characteristics of the age, sex, clinical manifestations, imaging features, evoked potential, blood immune antibody results, rate of cerebrospinal fluid routine biochemical synthesis oligoclonal band igg, extension, nerve dysfunction score spinal cord clinically isolated syndrome and the influence factors, such as the relationship between the outcome of multiple sclerosis.

Eligibility criteria:
inclusion criteria: diagnosis time and place: department of neurology, peking university third hospital from january 2010 to november 2020 diagnosed as a patient with clinically isolated spinal cord syndrome for the first time exclusion criteria: none
ipeer2peer program for adolescents with inflammatory bowel disease

Conditions: Inflammatory Bowel Diseases

Summary: the ipeer2peer program matches teens with inflammatory bowel disease (ibd) with an older mentor who has learned to manage their ibd well and can support them emotionally and socially. this study will compare two groups of teens: those who are in the ipeer2peer program and those in the control group (no mentor).

the ipeer2peer program matches teens with inflammatory bowel disease (ibd) with an older mentor who has learned to manage their ibd well and can support them emotionally and socially. this study will compare two groups of teens: those who are in the ipeer2peer program and those in the control group (no mentor). the proposed trial aims to examine the impact of the ipeer2peer program on self-management skills of youth with ibd (mentees) as well as health outcomes of peer mentors in the program. this innovative program leverages the internet, commonly used by youth, to improve access and acceptability of self-management interventions while fostering social engagement in youth with ibd, thereby potentially improving hrql.

Eligibility criteria:
inclusion criteria: * males and females 12-18 years old, * gastroenterologist-diagnosed ibd, * able to speak and read english, * access to a computer, smartphone or tablet capable of using free skype software (note: participants who do not have adequate internet access will be provided with portable internet devices), * willing and able to complete online measures. exclusion criteria: * significant cognitive impairments or * severe co-morbid illnesses (medical or psychiatric conditions) likely to influence hrql assessment (e.g., psychosis, active suicidal ideation), * participating in other peer support or self-management interventions
optokinetic virtual reality stimulation in unilateral vestibular hypofunction

Conditions: Vestibular Hypofunction

Summary: the study will be conducted on patients diagnosed with uvh who apply to prof. dr. mete i̇şeri ear, nose and throat diseases polyclinic and güneşli erdem hospital ear, nose and throat and vestibular rehabilitation unit. participants will be divided into 3 groups by simple randomization (closed envelope) method. to the vestibular rehabilitation group; a conventional rehabilitation program based on structured cawthorne cooksey exercises will be applied for 45 minutes once a week with the support of a physiotherapist for 8 weeks. to the optokinetic stimulation group; optokinetic stimulation will be given with virtual reality glasses, and to the combined group; participants in the vestibular exercise group will receive additional optokinetic stimulation. the application will be done once a week for 8 weeks. inclusion criteria for the study are; diagnosed with unilateral vestibular hypofunction with vng test, between the ages of 18-65, class a+ in the system usability scale (sus) and the percentage range being between 96-100%; exclusion criteria for the study are; bilateral vestibular hypofunction, visual impairment, neurological disorder and inability to communicate.


Eligibility criteria:
inclusion criteria: * diagnosed with unilateral vestibular hypofunction with vng test, * being between the ages of 18-65, * being in the a+ class on the system usability scale (scs) and having a value between 96-100 percentile exclusion criteria: * having bilateral vestibular hypofunction * having a visual impairment, * having a neurological disorder * inability to communicate

Keywords: unilateral vestibular hypofunction virtual reality optokinetic stimulation motion sickness
impact of a personalized medication plan on duration of treatment with potent opioids in acute non-cancer musculoskeletal pain.

Conditions: Acute Pathology of the Locomotor System

Summary: the aim of this study is to evaluate whether patients who benefit from a personalized pharmaceutical plan (ppp) during their hospitalization, allowing them to be informed and sensitized, are treated for a shorter period of time with strong opioids with a reduced risk of dependence compared to a management according to the usual modalities in the rheumatology services concerned.


Eligibility criteria:
inclusion criteria: * patient hospitalized in the rheumatology department * patient with acute pain in the context of a non-cancerous, non-traumatic, high-energy musculoskeletal pathology * patient for whom a prescription of strong opioid derivatives is initiated in rheumatology or patient for whom a prescription of strong opioid derivatives is maintained in rheumatology if the initial prescription has a maximum duration of 30 consecutive days prior to inclusion exclusion criteria: * patient with cancer or fibromyalgia already diagnosed at inclusion * patient with poor french language skills * taking a strong opioid treatment for more than 30 consecutive days prior to inclusion * person judged by the prescriber or pharmacist as not autonomous for the management of strong opioid treatment * patient already included in the study
the covid-rasi trial (covid-19)

Conditions: COVID-19; Cardiovascular Diseases

Summary: the covid-rasi study is an international randomized clinical trial that will evaluate the potential benefit of angiotensin modulators on clinical outcomes, in covid-19 patients. the purpose of this study is to determine if renin-angiotensin system inhibitors (rasi), with angiotensin-converting enzyme inhibitors (acei) or angiotensin ii receptor blockers (arb), has a beneficial effect in patients with covid-19 infections, by reducing icu admission, ventilator requirement or death. we would also like to determine if there are differences between acei and arb therapeutic treatments. with the increasing potential of long covid symptoms, at the 1 year follow up, a primary endpoint will be the quality of life of study participants, as assessed by ongoing symptoms and/or the standardized questionnaires.

the goal is to determine if rasi with acei or arb, has a beneficial effect in patients with covid-19 infections, by reducing hospitalizations, icu admission, ventilator requirement or death. this is a multi-centre study, conducted in major centres treating covid-19 patients in-hospital and in various outpatient settings. patients admitted to hospital or outpatients that test positive for covid-19 and meet the inclusion/exclusion criteria will be eligible to participate in this study. all study participants will not be on rasi (acei/arb) treatment at the time of consent. participants will be randomized to initiation of acei vs arb treatment vs no rasi treatment as part of care for covid-19 in a 1:1:1 ratio. the patient will be followed by their physician according to usual clinical care. sites will complete research-related follow-ups at 24 hours, 7 and 28 days to asssess patient's clinical status, side effects and the achievement of clinical endpoints by telephone interviews. phone call follow ups will also be conducted at 6 months and 12 months after enrollment in the study.

Eligibility criteria:
inclusion criteria: * patient with covid-19 diagnosis with laboratory confirmation within the last 30 days and * age 40 years old or greater if outpatient or age 18 years old or greater if inpatient (admitted to the hospital) at time of recruitment exclusion criteria: * contraindication to arb or acei, including severe aortic stenosis and angioedema * patients who are currently on active treatment with arb/acei * known bilateral renal artery stenosis * systolic bp ≤90 mmhg * egfr\<30 ml/min, if not receiving dialysis treatment * k\>5.5 mmol/l on screening laboratory testing * recent history of dizziness, vertigo, related to hypotension or orthostatic hypotension, that can lead to contraindication to acei/arbs * acute respiratory distress syndrome requiring invasive ventilation

Keywords: cardiovascular risk factors corona virus covid-19 severe acute respiratory syndrome coronavirus 2 (sars-cov-2) angiotensin-converting enzyme inhibitors acei renin-angiotensin system inhibitors rasi angiotensin receptor blockers arb
effect of supplementation of fish oil on non-alcoholic fatty liver disease in children

Conditions: Non-alcoholic Fatty Liver Disease

Summary: the aim of this study is to evaluate efficacy of fish oil (epa/dha) in children with non-alcoholic fatty liver disease.

76 children or adolescents aged 6-19 with nafld will be included in the study. diagnosis of nafld is set by increased alanine transaminase and features of liver steatosis on ultrasound. patients will be randomized to receive either fish oil (epa/dha, 400-1200mg) or placebo (sunflower oil) for 6 months. all children will be advised to reduce weight (dietetic intervention + increased physical activity). laboratory tests, liver ultrasound, anthropometric analysis will be performed at the start, after 3 months and 6 months.

Eligibility criteria:
inclusion criteria: * age 6-19 * overweight or obesity * alt activity over 130% of upper limit norm * hyperechogenicity of the liver on ultrasound exclusion criteria: * hcv, hbv infection * cholestasis * chronic/acute liver failure * alpha-1-antitrypsin deficiency * wilson disease * type 2 diabetes mellitus * beta-oxidation defects * alcohol consumption * history of parenteral nutrition * use of drugs

Keywords: fatty liver hepatitis insulin resistance unsaturated fatty acids nafld, children
the effects of inositol on glucose metabolism in patients with metabolic syndrome at risk of cardiac fibrosis

Conditions: Metabolic Syndrome; Cardiac Fibrosis

Summary: the study aims to evaluate the effects of an oral supplementation based on inositols and alpha-lactalbumin on principals metabolic parameters in patients with metabolic syndrome at risk of cardiac fibrosis


Eligibility criteria:
at least 3 of the following inclusion criteria: * triglycerides levels ≥ 150 mg/dl * hdl ≤ 40 mg/dl * fasting glycemia \> 100 mg/dl \<126 mg/dl * systolic pressure ≥ 130 mmhg or diastolic pressure ≥ 85 mmhg * hip circumference \> 102 cm in men or 88 cm in women
selection of potential predictors of worsening heart failure

Conditions: Heart Failure

Summary: multicentre study with the objective to correlate heart failure hospitalizations and deaths with home monitoring data in icd/crt-d recipients, in order to identify the combination of home monitoring data with the greatest sensitivity and specificity in predicting heart failure events. all data are prospectively collected.

home monitoring remotely provides continuous trends of potential hf-related variables with a sampling interval of 24 hours. although the predictive value of individual variables may be limited, a proper combination of more variables and their 24-hour sampling may allow developing a hm diagnostic algorithm to accurately predict hf worsening within given time windows. the objective of this study is to select the predictive variables which are most likely to be effectively included in a future algorithm. this is a multicentre, exploratory study with the objective to prospectively collect follow-up and home monitoring data from a population of subjects with indication for icd and/or crt-d implantation, to document hf hospitalizations and deaths and to correlate these events with hm data to identify the combination of hm data with the greatest sensitivity and specificity in predicting hf events. fifty first hospitalizations for worsening hf (adjudicated by an independent board) are necessary to reach the study objective (event driven study), which were initially assumed to be generated by 650 patients fulfilling inclusion and exclusion criteria. sample size estimation has been reviewed after an interim analysis.

Eligibility criteria:
inclusion criteria: * left ventricular ejection fraction (lvef) ≤ 35% * nyha class ii or iii heart failure * men and women 18 years of age or older * understand the nature of the procedure * give written informed consent exclusion criteria: * no indication or contraindication for icd or crt-d therapy * permanent af * nyha class iv heart failure * subjects with irreversible brain damage from preexisting cerebral disease; * subjects with acutely decompensated heart failure * expected heart transplantation within next six months or planned cardiac surgery within next 3 months * have a life expectancy of less than six months * presence of any disease, other than the subject's cardiac disease associated with a reduced likelihood of survival for the duration of the trial, (e.g. cancer) * unstable geographical residence (unable to anticipate to be resident in the area of the referring participating centre during the study period) and/or gsm-free residence * subjects who were not been implanted with icd or crt-d devices compatible with hm transmissions * age \<18 years * pregnancy

Keywords: heart failure remote monitoring lung edema patient monitoring prediction
healthetech lifestyle program

Conditions: Obesity

Summary: the purpose of the study is to determine the efficacy of resting metabolic rate (rmr) using bodygem and balancelog in helping overweight and obese individuals manage their weight.

the study plans are to develop and test the efficacy of a practical, structured, and time-limited behavioral intervention (healthelifestyle program) as a supplement to standard healthetech products. approximately 130 participants will be recruited and randomized to either the healthetech program (focusing on calorie and exercise goals using the balancelog for tracking), the healthelifestyle program (using step counters, monthly email letters and calls providing information on activity, nutrition, and weight loss), or a delayed treatment program (after 3 months undergo the intervention above).

Eligibility criteria:
inclusion criteria: healthy adult men and women, 18-60 years - exclusion criteria: not currently participating in a structured diet or exercise program -

Keywords: weight control compliance physical activity nutrition health behavior patient compliance
the effect of an exercise program on physical function after a spinal cord injury

Conditions: Spinal Cord Injury

Summary: this study would focus on adding a group exercise program to the usual therapy delivered in the hospital. we propose to design an exercise program that would be 30 minutes in length, 3 times per week. a medical doctor and physiotherapist would oversee the design and monitoring of the program. we believe that this program will: 1) increase the potential for better health, thus improving independence and quality of life; 2) help people make the move from therapist run exercise to self management of exercise; 3) engage the patient in the therapy process and place an expectation of active participation on the client; and 4) promote physical activity as part of a healthy lifestyle.

in total 30 participants admitted for spinal cord injury rehabilitation at gf strong rehabilitation centre will be randomly assigned to either cardiovascular training group or balance training group. the cardiovascular training group will receive their usual therapy plus 3 days of 30 minutes of exercise per week. this program will last for 6 weeks while the participant is in the hospital. the cardiovascular training program will include pushing and pulling on pulleys, wheeling over mats, punching a boxing bag, and using an arm ergometer. the balance training group will receive their usual therapy plus 3 days of 30 minutes of sitting balance activities. this program will last for 6 weeks while the participant is in the hospital. the balance training program will include sitting on mats - moving arm support from in front of the body to behind body, moving from sitting to lying and back up, and catching soft foam ball thrown directly to centre of chest and throwing it back.

Eligibility criteria:
inclusion criteria: 1. sustained a traumatic spinal cord injury, 2. 16-50 years of age, 3. able to push a manual wheelchair and arm ergometer, 4. able to participate in exercise three times per week for 30 minutes, 5. able to follow english instructions. exclusion criteria: 1. unstable cardiovascular status (congestive heart failure, uncontrolled hypertension, uncontrolled atrial fibrillation, or left ventricular failure), 2. significant musculo-skeletal problems (e.g., rheumatoid arthritis) or neurological conditions (e.g., parkinson's disease) due to conditions other than spinal cord injury, 3. increased pain with exercise.

Keywords: spinal cord injury exercise rehabilitation inpatient rct physical function
immunochemotherapy and allosct in patients with high risk cd33+ aml/mds

Conditions: Acute Myelogenous Leukemia; Myelodysplastic Syndrome

Summary: targeted immune therapy with gemtuzumab ozogamicin (mylotarg) in combination with chemotherapy followed by allogeneic stem cell transplantation will be given to patients with high risk acute myelogenous leukemia (aml) or myelodysplastic syndrome (mds).

gemtuzumab ozogamicin in combination with busulfan and cyclophosphamide (immunochemotherapy) conditioning followed by allogeneic stem cell transplantation + anti-thymocyte globulin (unrelated donors only) in patients with high risk cd33+aml or mds meeting eligibility criteria.

Eligibility criteria:
inclusion criteria: * disease status: * history of aml induction/reinduction failure * aml 1st complete remission (cr) with poor cytogenetics * aml 2nd cr with minimal residual disease (mrd) * aml 3rd cr * aml in refractory relapse but ≤25% bone marrow leukemia blasts * mds with \>6% bone marrow blasts at diagnosis * secondary mds with ≤5% bone marrow myeloblasts at diagnosis disease immunophenotype: • disease must express a minimum of \>/= 10% cd33+ for patients with aml organ function: • adequate renal function, adequate liver function, adequate cardiac function, adequate pulmonary function age: ≤25 years of age donor: matched family donor, unrelated cord blood donor, unrelated adult donor exclusion criteria: * patients with active central nervous system (cns) aml/mds disease at time of conditioning therapy * female patients who are pregnant * karnofsky \<50% or lansky \<50% if 10 years or less * age \>25 years * has received gemtuzumab in the previous 30 days or has not recovered from prior gemtuzumab therapy.

Keywords: targeted therapy leukemia mds immune therapy
pharmacokinetics of c1 esterase inhibitor in hereditary angioedema subjects

Conditions: Hereditary Angioedema

Summary: the study objective was to describe the pharmacokinetics (pk) of one or two doses of c1 esterase inhibitor (c1inh-nf) in hereditary angioedema (hae) subjects who were not experiencing an hae attack.


Eligibility criteria:
inclusion criteria: * enrolled in levp2005-1 (current or in the past) exclusion criteria: * c1 inhibitor infusion within the last 7 days * signs of any hae attack * hae attack within 7 days before actual infusion of c1inh-nf * change in the dosage of androgens in the last 14 days before the study * use of antifibrinolytics in the last 7 days before the study * change in oral conceptive medication in the last two months before the study * history of clinically relevant antibody development to c1 inhibitor * use of oral anticoagulant medication in the last 14 days * use of heparin within the last two days prior to the study * history of allergic reaction to c1 inhibitor or other blood products * current participation (or within the past 90 days) in any investigational drug study other than those sponsored by lev pharmaceuticals * pregnancy or lactation * b-cell malignancy * any clinically significant medical condition, such as renal failure, that in the opinion of the investigator would interfere with the subject's ability to participate in the study

Keywords: hereditary angioedema c1 esterase inhibitor (human)